Simplex Trading’s Xenetic Biosciences XBIO Stock Holding History

Simplex Trading’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,580	Closed	-$16K	–	11260
2022 Q1	$16K	Sell	1,580 -5,620	-78%	-$58.6K	﹤0.01%	8492
2021 Q4	$92K	Buy	+7,200	New	+$115K	﹤0.01%	6400

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Simplex Trading's XBIO Position: Q2 2023 in Review

Simplex Trading sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 136 shares.

Simplex Trading first reported a position in XBIO in Q4 2021 and held it in 3 quarters. The position peaked at $56K in Q4 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

Simplex Trading reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
Simplex Trading sold 136 Xenetic Biosciences shares in Q2 2023.
Simplex Trading first reported a position in Xenetic Biosciences in Q4 2021 and held it in 3 quarters.
Simplex Trading's Xenetic Biosciences position peaked at $56K in Q4 2021.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.